Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
M

ASCO® 2023 Insights: "RUBY Trial - PROs in Primary Advanced or Recurrent Endometrial Cancer for Pts Treated With Dostarlimab + Carboplatin/Paclitaxel vs. CP"

By Insights from 2023 ASCO® Annual Meeting FEATURING Mansoor Raza Mirza
By Insights from 2023 ASCO® Annual Meeting FEATURING Mansoor Raza Mirza
194 views
June 23, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Featured Video

20:14
Exelixis

Hypothetical Patient Case: RAI-R Metastatic Differentiated Thyroid C…

Feat. R. Alter, R. Shameem
GYN
08:10

Initial Efficacy & Safety Results From a Phase 2 ENGOT-ov60/GOG-3052…

Insights from 2023 ASCO® Annual Meeting

S. Banerjee

110 views
12:42

ASCO® 2023 Insights: "RUBY Trial - PROs in Primary Advanced or Recur…

Insights from 2023 ASCO® Annual Meeting

M. Raza Mirza

194 views
07:24

ASCO® 2023 Insights: "BRCA1 and RAD51 Methylation Impact on Outcome …

Insights from 2023 ASCO® Annual Meeting

H. Blons

143 views
06:29

ASCO® 2023 Insights: "TEDOVA Trial - Neo-Epitope Based Vaccine Alone…

Insights from 2023 ASCO® Annual Meeting

A. Leary

380 views
09:28

ASCO® 2023 Insights: "A Phase II Basket Trial of Dual Anti-CTLA-4 an…

Insights from 2023 ASCO® Annual Meeting

Y. Chae

162 views